New drug - Cholestagel for hyperlipidaemia

Genzyme has launched Cholestagel (Colesevalam) - indicated as an adjunct to diet in primary hypercholesterolaemia either with a statin for patients inadequately controlled on statin alone, or as monotherapy when a statin is inappropriate or not tolerated.

Colesevelam is a bile acid sequestrant preventing bile acid reabsorption. As the bile acid pool becomes depleted, hepatic conversion of cholesterol into bile acids is promoted, resulting in decreased serum low-density lipoprotein (LDL) cholesterol levels.

A study1 evaluated the efficacy of colesevelam in patients with primary hypercholesterolaemia, randomised to receive placebo or colesevelam for 24 weeks. In each colesevelam treatment group, end point LDL cholesterol levels were significantly decreased compared with baseline. Colesevelam lowered mean LDL cholesterol levels by nine to 18 per cent in a dose-dependent manner.

Another study2 evaluated the efficacy of colesevelam alone and in combination with simvastatin. The mean LDL cholesterol levels declined by 4 per cent in the placebo group, 26 per cent in the colesevelam (3.8g daily) group and 42 per cent in the colesevelam and simvastatin combination group (P<0.0001).

A third study3 evaluated the efficacy of colesevelam alone and in combination with atorvastatin. LDL cholesterol reductions with combination therapy (48 per cent) were statistically superior to colesevelam (12 per cent) or low-dose atorvastatin (38 per cent) alone, but similar to those achieved with atorvastatin 80mg daily (53 per cent).

1. Insull W, Toth P, Mullican W et al. Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: a 24-week randomised controlled trial. Mayo Clin Proc 2001: 76; 971–82.
2. Knapp H, Schrott H, Ma P et al. Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. Am J Med 2001: 110; 352–60.
3. Hunninghake D, Insull W, Toth P et al. Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively. Atherosclerosis 2001: 158; 407–16.


Further information: Genzyme 01865 405200

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from MIMS

An elderly woman with one arm in a plaster cast sits resting both hands on her walker

Doctors urge NICE to reverse decision on new osteoporosis drug

More than NHS 100 clinicians have called on NICE to...

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

Image of both strengths of Seffalair Spiromax inhaler side by side.

New salmeterol/fluticasone dry powder inhaler for asthma

Seffalair Spiromax is the sixth dry powder salmeterol/fluticasone...

An older man in a blue shirt and beige trousers leans forward on a sofa rubbing his painful lower back. Promoted

Established muscle relaxant offers new approach to managing back pain

Sponsored by Mibe Pharma

A muscle relaxant that has been used for decades outside the UK may provide an alternative to current treatments for low back pain, explains Dr Sunny Nayee, consultant in anaesthesia and pain medicine at Imperial College NHS Healthcare Trust.

Sponsored by Mibe Pharma UK Ltd. UK/MYO/21/044; December 2021.

Click here to view prescribing information for Myopridin® (pridinol mesilate)